Characterization of prostacyclin synthesis in cultured human arterial smooth muscle cells, venous endothelial cells and skin fibroblasts

Abstract

The interaction of human platelets with one another and with the blood vessel wall is thought to be regulated in part by a balance between two arachidonic acid metabolites: thromboxane A 2, synthesized by platelets, and prostacyclin (PGI 2), synthesized by the vessel wall. We have studied the ability of cultured human vascular cells to synthesize PGI 2 from arachidonic acid. Four strains of human arterial smooth muscle cells synthesized a mean of 1.36 ng PGI 2 per 10 5 cells, with a range of 0.2–5.3 ng PGI 2 per 10 5 cells among the different strains. Human umbilical vein endothelial cells synthesized a mean of 7.16 ng PGI 2 per 10 5 cells with a range of 2.3–14.0 ng per 10 5 cells. In contrast, cultured human diploid skin fibroblasts synthesized only 0.27 ng PGI 2 per 10 5 cells with a range of 0.05–0.6 ng per 10 5 cells. When cultured cells were mixed with platelets, PGI 2 synthesis from added arachidonate was reduced rather than stimulated. Thus the major precursor cyclic endoperoxides utilized for PGI 2 synthesis are formed within the cells and not from endoperoxides synthesized by platelet cyclooxygenase. Aspirin has been proposed as an anti-thrombotic agent. Aspirin could be ineffective, however, if it inhibited not only platelet cyclooxygenase but that of vessel wall cells as well. Measurement of the rate constant or potency for aspirin inhibition of PGI 2 synthesis in cultured cells indicates that the cyclooxygenase in both cell types of the blood vessel wall is 14–44 fold less sensitive to aspirin inactivation than that in platelets, and appropriate levels of aspirin can selectively block human platelet thromboxane A 2 synthesis without compromising the capacity of the vasculature to produce PGI 2.